Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer: A Phase 1 Trial

IMPORTANCE: Programmed cell death 1 (PD-1) antibodies have shown substantial survival benefit in patients with advanced non–small cell lung cancer (NSCLC). Toripalimab is a promising and practicable PD-1 antibody; however, its performance in NSCLC has not been established. OBJECTIVES: To assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhijie, Ying, Jianming, Xu, Jiachen, Yuan, Pei, Duan, Jianchun, Bai, Hua, Guo, Changyuan, Li, Lin, Yang, Zhenlin, Wan, Rui, Fei, Kailun, Zhao, Zhe, Du, Xinyang, Zhao, Junhui, Lv, Ning, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536589/
https://www.ncbi.nlm.nih.gov/pubmed/33017026
http://dx.doi.org/10.1001/jamanetworkopen.2020.13770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536589/
https://www.ncbi.nlm.nih.gov/pubmed/33017026
http://dx.doi.org/10.1001/jamanetworkopen.2020.13770

Ejemplares similares